Developer docs
API playgroundTry for free, no card

Search company profiles

Syntekabio

Full company profile

uuid00051k5

Namestring
Syntekabio
Legal namestring
Syntekabio, Inc.
Websiteurl
syntekabio.com
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Syntekabio is a South Korea-based AI drug discovery company listed on KOSDAQ (ticker: 226330), founded in 2009 and headquartered in Daejeon. The company operates an integrated AI drug discovery platform across three therapeutic modalities: small molecules (SM-ARS), antibodies (AB-ARS), and neoantigens/cancer vaccines (NEO-ARS), underpinned by two core AI engines — DEEPMATCHER (a language model for protein-compound interaction prediction) and LM-VS (language model-based virtual screening across 10 billion compounds). The platform is powered by a proprietary 15MW AI Bio Supercomputing (ABS) Data Center in Daejeon featuring 5,000+ GPU clusters and a patented termite-mound-inspired natural convection cooling system achieving PUE of 1.13.

The company monetizes through multiple channels: SaaS subscriptions for LM-VS at $20,000 per target protein (delivering top 200 candidates within 3 weeks), fee-for-service custom project collaborations, pre-validated AI Asset Programs (covering targets such as BCL2, BTK, CDK2/4/6, KRAS, FGFR1/2/3), PaaS subscriptions planned for H2 2025, and newly launched data center IDC colocation services. Customers include global pharma and biotech firms such as Memorial Sloan Kettering Cancer Center, MetaVia, Pragma Bio, OCMS Bio, and Rudacure, alongside an unnamed Nasdaq-listed TPD company and the world's largest animal health company. H1 2025 disclosed revenue was KRW 1.2 billion (~USD 870K), with over KRW 1.0 billion generated from the DeepMatcher platform alone. GTM operates through direct B2B sales, supplemented by product-led self-serve access via the LM-VS SaaS platform launched for global markets in 2025, and academic publication-driven thought leadership.

Short descriptiontext

Syntekabio is a KOSDAQ-listed South Korean AI drug discovery company offering an integrated platform spanning small molecules, antibodies, and neoantigens, powered by proprietary language models and a 15MW AI Bio Supercomputing Center, serving global pharma and biotech clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, drug development platform, pharmaceutical AI, biotech software, computational biology
Industry5 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1AI Drug Discovery Platform Services
TypeSubscription Recurring
Description

Revenue generated from providing access to AI drug discovery platforms including DeepMatcher and LM-VS. In H1 2025, over KRW 1.0 billion was generated from the DeepMatcher platform alone, demonstrating commercial viability of the technology. The company launched LM-VS as a SaaS product for global markets in H1 2025, with an upgraded PaaS version planned for H2 2025.

syntekabio.com
2Data Center Colocation / IDC Leasing
TypeManaged Services
Description

Revenue from leasing colocation services at the proprietary AI Bio Supercomputing (ABSC) data center. Syntekabio has signed contracts with two clients with further negotiations ongoing. Expected annual recurring revenue of KRW 2 billion with potential to reach KRW 3 billion at full capacity.

syntekabio.com
3System Integration (SI) Services
TypeProfessional Services
Description

Newly established SI division generating revenue from services such as eCommerce development and website development projects. First contract valued at approximately KRW 100 million secured in Q2 2025, with ongoing contract wins in Q3.

syntekabio.com
4AI-Driven Asset Programs (Pre-validated Drug Candidate Packages)
TypeTransaction Fee
Description

Revenue from selling pre-validated, AI-screened drug candidate packages (Asset Program) to pharmaceutical companies for immediate research use. Candidates include targets such as BCL2, BTK, CDK2/4/6, FGFR1/2/3, KRAS, and others. Packages include target-specific ELISA and expression data in standardized format.

qa.syntekabio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Pricing details1 tier
1LM-VS SaaS per target protein virtual screening
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$20,000 per target protein for complete hit discovery. Deliverables include top 200 candidates report + structure dataset. Timeline: within 3 weeks. Up to 50 iterative AI optimization cycles. 10 billion compound library (Enamine, Synple, SAVI & ZINC).

vs.syntekabio.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 7 records shown
1DeepMatcher®
Description

AI-driven drug candidate discovery platform for protein-compound interaction prediction

qa.syntekabio.com
+6 more records
Core offering1 text field

Syntekabio is an AI-driven drug discovery company that develops and operates proprietary software platforms (SM-ARS, AB-ARS, NEO-ARS, DEEPMATCHER, LM-VS) used by pharmaceutical and biotechnology companies to identify and optimize drug candidates. The company also operates a 15MW AI Bio Supercomputing (ABS) Data Center that supports its drug discovery workloads and provides colocation services, alongside asset programs that progress selected therapeutic candidates through development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 3x faster drug discovery timelines
+7 more records
Product overview1 text field

Syntekabio is an AI-powered drug discovery company offering a platform-plus-modules architecture. The core AI Drug Discovery Platform consists of five interconnected products: SM-ARS® for small molecule drug discovery, AB-ARS® for antibody candidate design, NEO-ARS® for neoantigen discovery and cancer vaccine design, DEEPMATCHER® as the underlying AI language model for protein-compound interaction prediction, and LM-VS™ for large-scale virtual screening of 10 billion compounds. These platforms are powered by the company's proprietary AI Bio Supercomputing (ABS) Data Center in Daejeon. The Asset Program provides pre-validated, ready-to-use drug candidate packages as an add-on offering. The company also operates data center colocation services and system integration divisions.

Product and service7 records
1SM-ARS (Small Molecule AI-driven Research Suite)
CategoryDrug Discovery Platform
2AB-ARS (Antibody AI-driven Research Suite)
CategoryDrug Discovery Platform
3NEO-ARS (New Entity Optimization AI-driven Research Suite)
CategoryDrug Discovery Platform
Description

AI platform focused on novel entity optimization for new drug candidates, including multi-parameter property prediction and candidate prioritization.

4DEEPMATCHER
CategoryDrug Discovery Platform
Description

AI-based molecular matching and screening platform that pairs compounds with biological targets to accelerate early-stage drug discovery.

5LM-VS (Language Model - Virtual Screening)
CategoryDrug Discovery Platform
Description

Language model-based virtual screening tool that uses natural language processing and deep learning to predict molecular activity and properties.

6Asset Program
CategoryDrug Development Program
Description

Therapeutic asset program in which Syntekabio identifies and advances selected drug candidates through preclinical development using its AI platforms.

7AI Bio Supercomputing (ABS) Data Center
CategoryInfrastructure Services
Description

15MW-class AI-focused data center providing high-performance computing infrastructure and colocation services for AI workloads in life sciences.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ongoing AI collaboration using Syntekabio's DeepMatcher platform to confirm therapeutic targets for MetaVia's oral GPR119 agonist vanoglipel (DA-1241). AI modeling identified inflammatory diseases, cardiometabolic disorders, and cancer as top predicted therapeutic areas, supporting development for MASH and type 2 diabetes. Phase 2a clinical data showed direct hepatic activity, improved glucose metabolism, and favorable safety profile in 109 patients over 16 weeks. Collaboration continues to explore additional indications and optimize the drug's therapeutic profile.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Expanded ongoing collaboration with MSK to include research on a second oncology target. Syntekabio utilizes its AI platforms LM-VS and DeepMatcher to perform virtual screening and deliver candidate compounds for validation and testing at MSK's laboratories.

3Pragma Bio
Strategic tierMajorTypeStrategic or Co-development Partner
Description

KRW 4.5 billion deal with US-based Pragma Bio to discover targets related to inflammatory bowel disease (IBD) and conduct preclinical research. Represents a significant international contract for Syntekabio.

syntekabio.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

US-based antibody discovery and engineering firm conducting antibody optimization and efficacy validation for undisclosed targets with Syntekabio. The two companies co-launched an AI-based one-shot antibody screening platform, expanding Syntekabio's global research network.

Strategic tierStandardTypeStrategic or Co-development Partner
Description

Korean biopharma R&D firm collaborating with Syntekabio for anti-cancer candidate identification using the company's AI drug discovery platforms.

6Undisclosed U.S. Nasdaq-listed TPD Company
Strategic tierStandardTypeStrategic or Co-development Partner
Description

U.S. Nasdaq-listed company specializing in Target Protein Degradation (TPD) has entered into first and second stage compound discovery contracts with Syntekabio.

syntekabio.com
7Undisclosed World's Largest Animal Health Company
Strategic tierStandardTypeStrategic or Co-development Partner
Description

Co-development of veterinary therapeutics with the world's largest animal health company using Syntekabio's proprietary AI platforms.

syntekabio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Physics-based computational chemistry and AI platform for drug discovery, including virtual screening and molecular dynamics. Syntekabio's 3D docking and flexible-mold approach in DeepMatcher competes directly with Schrödinger's LiveDesign and Glide platforms.

TypeDirect peer
Description

AI-driven small molecule discovery platform using convolutional neural networks for virtual screening across massive compound libraries. Directly comparable to LM-VS in targeting ultra-fast, large-scale hit identification for pharma partners.

TypeDirect peer
Description

AI and quantum physics-based drug discovery company combining computation with laboratory automation. Operates similar platform-plus-services model with major pharma collaborations, comparable to Syntekabio's platform offerings and partnership pipeline.

TypeRegional player
Description

Korean AI biotech focused on target identification and drug repurposing using deep learning on omics data. Comparable in applying AI/ML to early-stage drug discovery and operating from the Korean ecosystem with similar investor profiles.

TypeRegional player
Description

Korean AI drug discovery company offering end-to-end platforms for target identification, lead generation, and drug repurposing. Closest regional peer given shared Korean ecosystem, comparable platform approach, and overlapping customer base in domestic pharma.

TypeDirect peer
Description

AI drug discovery company applying knowledge graphs and machine learning to identify novel targets and drug candidates. Comparable in combining biomedical data, AI models, and pharma collaborations to accelerate discovery.

TypeDirect peer
Description

AI-driven drug discovery company offering end-to-end platforms for target identification, generative chemistry, and clinical prediction. Directly comparable to Syntekabio's DeepMatcher and LM-VS offerings in applying AI/ML to small molecule discovery, with similar focus on pharma collaborations.

TypeDirect peer
Description

AI-first biotech combining high-throughput experimentation with machine learning for drug discovery across small molecules and biologics. Comparable business model of platform-plus-pipeline with a strong supercomputing/data infrastructure component similar to Syntekabio's ABSC.

9Iambic Therapeutics
TypeEmerging player
Description

AI-driven drug discovery platform using novel neural network architectures for predicting molecular properties and designing therapeutics. Comparable as a smaller, AI-native platform player pursuing pharma partnerships and SaaS-style access to discovery tools.

TypeEmerging player
Description

Korean AI-based drug discovery company using proprietary platforms for novel target identification and small molecule development. Comparable in applying AI to reduce drug discovery timelines and costs, though at smaller scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Syntekabio

AI Drug Discovery Softwaresyntekabio.com

Syntekabio is a KOSDAQ-listed South Korean AI drug discovery company offering an integrated platform spanning small molecules, antibodies, and neoantigens, powered by proprietary language models and a 15MW AI Bio Supercomputing Center, serving global pharma and biotech clients.

What Syntekabio does

Syntekabio is a South Korea-based AI drug discovery company listed on KOSDAQ (ticker: 226330), founded in 2009 and headquartered in Daejeon. The company operates an integrated AI drug discovery platform across three therapeutic modalities: small molecules (SM-ARS), antibodies (AB-ARS), and neoantigens/cancer vaccines (NEO-ARS), underpinned by two core AI engines — DEEPMATCHER (a language model for protein-compound interaction prediction) and LM-VS (language model-based virtual screening across 10 billion compounds). The platform is powered by a proprietary 15MW AI Bio Supercomputing (ABS) Data Center in Daejeon featuring 5,000+ GPU clusters and a patented termite-mound-inspired natural convection cooling system achieving PUE of 1.13.

The company monetizes through multiple channels: SaaS subscriptions for LM-VS at $20,000 per target protein (delivering top 200 candidates within 3 weeks), fee-for-service custom project collaborations, pre-validated AI Asset Programs (covering targets such as BCL2, BTK, CDK2/4/6, KRAS, FGFR1/2/3), PaaS subscriptions planned for H2 2025, and newly launched data center IDC colocation services. Customers include global pharma and biotech firms such as Memorial Sloan Kettering Cancer Center, MetaVia, Pragma Bio, OCMS Bio, and Rudacure, alongside an unnamed Nasdaq-listed TPD company and the world's largest animal health company. H1 2025 disclosed revenue was KRW 1.2 billion (~USD 870K), with over KRW 1.0 billion generated from the DeepMatcher platform alone. GTM operates through direct B2B sales, supplemented by product-led self-serve access via the LM-VS SaaS platform launched for global markets in 2025, and academic publication-driven thought leadership.

Syntekabio firmographics

Firmographics
Name
Syntekabio
Legal name
Syntekabio, Inc.
Website
https://syntekabio.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Syntekabio is a KOSDAQ-listed South Korean AI drug discovery company offering an integrated platform spanning small molecules, antibodies, and neoantigens, powered by proprietary language models and a 15MW AI Bio Supercomputing Center, serving global pharma and biotech clients.
Ownership category
akta.pro rank

Syntekabio industry classification

Industry
Product category
AI Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Drug development platform
  • Pharmaceutical AI
  • Biotech software
  • Computational biology

Where Syntekabio is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Syntekabio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. AI Drug Discovery Platform Services: Revenue generated from providing access to AI drug discovery platforms including DeepMatcher and LM-VS. In H1 2025, over KRW 1.0 billion was generated from the DeepMatcher platform alone, demonstrating commercial viability of the technology. The company launched LM-VS as a SaaS product for global markets in H1 2025, with an upgraded PaaS version planned for H2 2025.
  2. Data Center Colocation / IDC Leasing: Revenue from leasing colocation services at the proprietary AI Bio Supercomputing (ABSC) data center. Syntekabio has signed contracts with two clients with further negotiations ongoing. Expected annual recurring revenue of KRW 2 billion with potential to reach KRW 3 billion at full capacity.
  3. System Integration (SI) Services: Newly established SI division generating revenue from services such as eCommerce development and website development projects. First contract valued at approximately KRW 100 million secured in Q2 2025, with ongoing contract wins in Q3.
  4. AI-Driven Asset Programs (Pre-validated Drug Candidate Packages): Revenue from selling pre-validated, AI-screened drug candidate packages (Asset Program) to pharmaceutical companies for immediate research use. Candidates include targets such as BCL2, BTK, CDK2/4/6, FGFR1/2/3, KRAS, and others. Packages include target-specific ELISA and expression data in standardized format.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goLM-VS SaaS per target protein virtual screening

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Syntekabio product offering

Product offering

Core offering

Syntekabio is an AI-driven drug discovery company that develops and operates proprietary software platforms (SM-ARS, AB-ARS, NEO-ARS, DEEPMATCHER, LM-VS) used by pharmaceutical and biotechnology companies to identify and optimize drug candidates. The company also operates a 15MW AI Bio Supercomputing (ABS) Data Center that supports its drug discovery workloads and provides colocation services, alongside asset programs that progress selected therapeutic candidates through development.

Product overview

Syntekabio is an AI-powered drug discovery company offering a platform-plus-modules architecture. The core AI Drug Discovery Platform consists of five interconnected products: SM-ARS® for small molecule drug discovery, AB-ARS® for antibody candidate design, NEO-ARS® for neoantigen discovery and cancer vaccine design, DEEPMATCHER® as the underlying AI language model for protein-compound interaction prediction, and LM-VS™ for large-scale virtual screening of 10 billion compounds. These platforms are powered by the company's proprietary AI Bio Supercomputing (ABS) Data Center in Daejeon. The Asset Program provides pre-validated, ready-to-use drug candidate packages as an add-on offering. The company also operates data center colocation services and system integration divisions.

Differentiator

Problem solved

Functional benefit

Brands

  • DeepMatcher®: AI-driven drug candidate discovery platform for protein-compound interaction prediction
  • LM-VS™
  • SM-ARS®
  • AB-ARS®
  • NEO-ARS®
  • ABSC (AI Bio Supercomputing Center)
  • STB Cloud

Products and services

  • SM-ARS (Small Molecule AI-driven Research Suite)
  • AB-ARS (Antibody AI-driven Research Suite)
  • NEO-ARS (New Entity Optimization AI-driven Research Suite) AI platform focused on novel entity optimization for new drug candidates, including multi-parameter property prediction and candidate prioritization.
  • DEEPMATCHER AI-based molecular matching and screening platform that pairs compounds with biological targets to accelerate early-stage drug discovery.
  • LM-VS (Language Model - Virtual Screening) Language model-based virtual screening tool that uses natural language processing and deep learning to predict molecular activity and properties.
  • Asset Program Therapeutic asset program in which Syntekabio identifies and advances selected drug candidates through preclinical development using its AI platforms.
  • AI Bio Supercomputing (ABS) Data Center 15MW-class AI-focused data center providing high-performance computing infrastructure and colocation services for AI workloads in life sciences.

Quantifiable outcome

  • 3x faster drug discovery timelines
  • +7 more outcomes

Companies that use Syntekabio

Customer profile

Named customers6 records

Segments1 record

Ideal customer profiles1 record

Syntekabio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability8 records

Feature7 records

Syntekabio partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, major and standard.

  • MetaVia Inc.coreStrategic or Co-development PartnerOngoing AI collaboration using Syntekabio's DeepMatcher platform to confirm therapeutic targets for MetaVia's oral GPR119 agonist vanoglipel (DA-1241). AI modeling identified inflammatory diseases, cardiometabolic disorders, and cancer as top predicted therapeutic areas, supporting development for MASH and type 2 diabetes. Phase 2a clinical data showed direct hepatic activity, improved glucose metabolism, and favorable safety profile in 109 patients over 16 weeks. Collaboration continues to explore additional indications and optimize the drug's therapeutic profile.
  • Memorial Sloan Kettering Cancer Center (MSK)coreStrategic or Co-development PartnerExpanded ongoing collaboration with MSK to include research on a second oncology target. Syntekabio utilizes its AI platforms LM-VS and DeepMatcher to perform virtual screening and deliver candidate compounds for validation and testing at MSK's laboratories.
  • Pragma BiomajorStrategic or Co-development PartnerKRW 4.5 billion deal with US-based Pragma Bio to discover targets related to inflammatory bowel disease (IBD) and conduct preclinical research. Represents a significant international contract for Syntekabio.
  • OCMS BiomajorStrategic or Co-development PartnerUS-based antibody discovery and engineering firm conducting antibody optimization and efficacy validation for undisclosed targets with Syntekabio. The two companies co-launched an AI-based one-shot antibody screening platform, expanding Syntekabio's global research network.
  • RudacurestandardStrategic or Co-development PartnerKorean biopharma R&D firm collaborating with Syntekabio for anti-cancer candidate identification using the company's AI drug discovery platforms.
  • Undisclosed U.S. Nasdaq-listed TPD CompanystandardStrategic or Co-development PartnerU.S. Nasdaq-listed company specializing in Target Protein Degradation (TPD) has entered into first and second stage compound discovery contracts with Syntekabio.
  • Undisclosed World's Largest Animal Health CompanystandardStrategic or Co-development PartnerCo-development of veterinary therapeutics with the world's largest animal health company using Syntekabio's proprietary AI platforms.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Syntekabio competitors and assessment

Company assessment

Direct peers

  • Schrödinger: Physics-based computational chemistry and AI platform for drug discovery, including virtual screening and molecular dynamics. Syntekabio's 3D docking and flexible-mold approach in DeepMatcher competes directly with Schrödinger's LiveDesign and Glide platforms.
  • Atomwise: AI-driven small molecule discovery platform using convolutional neural networks for virtual screening across massive compound libraries. Directly comparable to LM-VS in targeting ultra-fast, large-scale hit identification for pharma partners.
  • XtalPi: AI and quantum physics-based drug discovery company combining computation with laboratory automation. Operates similar platform-plus-services model with major pharma collaborations, comparable to Syntekabio's platform offerings and partnership pipeline.
  • BenevolentAI: AI drug discovery company applying knowledge graphs and machine learning to identify novel targets and drug candidates. Comparable in combining biomedical data, AI models, and pharma collaborations to accelerate discovery.
  • Insilico Medicine: AI-driven drug discovery company offering end-to-end platforms for target identification, generative chemistry, and clinical prediction. Directly comparable to Syntekabio's DeepMatcher and LM-VS offerings in applying AI/ML to small molecule discovery, with similar focus on pharma collaborations.
  • Recursion Pharmaceuticals: AI-first biotech combining high-throughput experimentation with machine learning for drug discovery across small molecules and biologics. Comparable business model of platform-plus-pipeline with a strong supercomputing/data infrastructure component similar to Syntekabio's ABSC.

Regional players

  • Deargen: Korean AI biotech focused on target identification and drug repurposing using deep learning on omics data. Comparable in applying AI/ML to early-stage drug discovery and operating from the Korean ecosystem with similar investor profiles.
  • Standigm: Korean AI drug discovery company offering end-to-end platforms for target identification, lead generation, and drug repurposing. Closest regional peer given shared Korean ecosystem, comparable platform approach, and overlapping customer base in domestic pharma.

Emerging players

  • Iambic Therapeutics: AI-driven drug discovery platform using novel neural network architectures for predicting molecular properties and designing therapeutics. Comparable as a smaller, AI-native platform player pursuing pharma partnerships and SaaS-style access to discovery tools.
  • Pharos iBio: Korean AI-based drug discovery company using proprietary platforms for novel target identification and small molecule development. Comparable in applying AI to reduce drug discovery timelines and costs, though at smaller scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Syntekabio social profiles

Digital presence

Syntekabio compliance and trust

Trust signal

Compliance1 record

Syntekabio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Syntekabio leadership team

Management profile

Number of profiles

Profiles1 record

Syntekabio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Syntekabio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syntekabio

What does Syntekabio do?

Syntekabio is an AI-driven drug discovery company that develops and operates proprietary software platforms (SM-ARS, AB-ARS, NEO-ARS, DEEPMATCHER, LM-VS) used by pharmaceutical and biotechnology companies to identify and optimize drug candidates. The company also operates a 15MW AI Bio Supercomputing (ABS) Data Center that supports its drug discovery workloads and provides colocation services, alongside asset programs that progress selected therapeutic candidates through development.

Is Syntekabio a public or private company?

Syntekabio is a public company. It is classified as public and is currently operating.

When was Syntekabio founded?

Syntekabio was founded in 2009. It employs 11 to 50 people.

Where is Syntekabio based?

Syntekabio is headquartered in New York, United States, in the North America region.

How does Syntekabio make money?

Four revenue lines are on record. AI Drug Discovery Platform Services are the primary driver. The others are data Center Colocation / IDC Leasing, system Integration (SI) Services and AI-Driven Asset Programs (Pre-validated Drug Candidate Packages).

Who are Syntekabio's main competitors?

Direct peers on record are Schrödinger, Atomwise, XtalPi, BenevolentAI, Insilico Medicine and Recursion Pharmaceuticals. Regional players are Deargen and Standigm. Emerging players are Iambic Therapeutics and Pharos iBio.

Does Syntekabio have an API?

No public API is recorded for Syntekabio.

What industry is Syntekabio in?

Syntekabio's product category is AI Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingSyntekaBio Extends Largest Shareholder’s Share Pledge to Nov. 30, 2026SyntekaBio extended its largest shareholder's share pledge to November 30, 2026, from October 30, 2026. The pledge covers 2.8 million shares against KRW 2.85 billion in borrowings, with collateral valued at KRW 5.04 billion. Full enforcement would reduce the shareholder's stake to 3.13% from 14.67%, potentially triggering a change in the largest shareholder.The future of tradingSyntekaBio Grants Stock Options for 392,000 Shares to Directors, EmployeesSyntekaBio granted stock options covering 392,000 common shares to 33 directors and employees on Oct. 16, 2026. The award represents 1.62% of issued shares, bringing total outstanding options to 1,132,500. Exercise is permitted from Oct. 16, 2028, through Oct. 15, 2031, with a two-year service requirement.Investing.comAI modeling confirms therapeutic targets for MetaVia’s vanoglipel By Investing.comMetaVia Inc. announced that AI-based modeling conducted through its collaboration with Syntekabio has confirmed key disease targets, including inflammatory diseases, cardiometabolic disorders, and cancer, for its oral G-protein-coupled receptor 119 agonist vanoglipel (DA-1241). The findings align with the company's focus on developing vanoglipel for metabolic dysfunction-associated steatohepatitis (MASH) and potentially type 2 diabetes, building on positive Phase 2a clinical data showing direct hepatic activity, improvements in glucose metabolism, and a favorable safety profile in 109 patients over 16 weeks. MetaVia plans to continue using Syntekabio's AI platform to explore additional indications and optimize the therapeutic profile while also developing DA-1726, an oxyntomodulin analogue, for obesity treatment.PR NewswireMetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for VanoglipelMetaVia Inc. announced positive AI-modeling results from its ongoing collaboration with Syntekabio using the DeepMatcher® platform, confirming key inflammatory and cardiometabolic target engagement for its oral GPR119 agonist vanoglipel (DA-1241). The AI analysis identified inflammatory diseases, cardiometabolic disorders, and cancer as top predicted target areas, supporting development in metabolic dysfunction-associated steatohepatitis (MASH) and potential Type 2 diabetes. The company noted Phase 2a clinical results demonstrating direct hepatic activity, improvements in glucose metabolism, and favorable safety profile in 109 patients over 16 weeks.EIN PresswireSyntekabio Publishes Peer-Reviewed Study in Molecules on LLM-Driven Small-Molecule Binding PredictionSyntekabio announced the publication of a peer-reviewed study in Molecules that introduces 3bmGPT, a large language model designed to analyze protein-ligand interactions by translating structural contacts into a text format. The model was trained on approximately 60 million interaction sentences from 2,900 proteins and is used in the company's LM-VS platform for drug discovery.The Manila TimesSyntekabio to Showcase AI-Driven Drug Discovery Solutions at Biotech Showcase 2025Syntekabio will showcase its AI-driven drug discovery solutions at Biotech Showcase 2025 in San Francisco, January 13-15, 2025. The company highlights its 'Develop Now, Pay Later' offer and STB LaunchPad program powered by DeepMatcher technology. CEO Jongsun Jung emphasized the goal of accelerating novel therapies.GlobeNewswireSyntekabio to Showcase AI-Driven Drug Discovery Solutions at Biotech Showcase 2025Syntekabio will showcase its AI-driven drug discovery solutions at Biotech Showcase 2025 in San Francisco, January 13–15, 2025. The company highlights its 'Develop Now, Pay Later' offer and STB LaunchPad program powered by DeepMatcher technology. CEO Jongsun Jung emphasized the goal of accelerating novel therapies.GlobeNewswireSyntekabio to Showcase AI-Driven Drug Discovery Solutions at Biotech Showcase 2025Syntekabio will showcase its AI-driven drug discovery solutions at Biotech Showcase 2025 in San Francisco, January 13–15, 2025. The company highlights its 'Develop Now, Pay Later' offer and STB LaunchPad program powered by DeepMatcher technology. CEO Jongsun Jung emphasized the goal of accelerating novel therapies.YahooSyntekabio Appoints Joonhyuk Choi, Former Target Health CEO, as Head of US OperationsSyntekabio appointed Joonhyuk Choi, former CEO of Target Health, as Head of US Operations. He brings over 25 years of pharmaceutical experience, including leading clinical trial software and FDA approval processes. The company expects his expertise to enhance strategic partnerships and revenue initiatives.EnamineNews & Press ReleasesThe provided text is a collection of unrelated press releases and news snippets rather than a single cohesive article. The content primarily details various strategic partnerships and collaborations involving the chemical supplier Enamine with entities such as Syntekabio, K-MEDI HUB, Recursion, and Proteros biostructures to advance AI-driven drug discovery and compound screening. These announcements span from late 2023 to September 2024, covering different geographic regions and therapeutic targets.